Liraglutide and Renal Outcomes in Type 2 Diabetes.

@article{Boer2017LiraglutideAR,
  title={Liraglutide and Renal Outcomes in Type 2 Diabetes.},
  author={Ian H de Boer},
  journal={The New England journal of medicine},
  year={2017},
  volume={377 22},
  pages={
          2198
        }
}
To the Editor: In reporting the results of the secondary analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, Mann et al. (Aug. 31 issue)1 provide details on the previously reported prespecified composite renal outcome that was 22% lower with long-term use of the human glucagon-like peptide 1 (GLP-1) analogue liraglutide than with placebo.2 That result was driven by a 26% reduction in new-onset persistent macroalbuminuria… CONTINUE READING